HK Stock Market Move | CHINA POWER(02380) climbs over 3% in the morning with a significant positive turnaround in the company's free cash flow over the past 25 years. The proportion of clean energy revenue has increased.
China Power (02380) rose more than 3% in the morning, as of the time of writing, it is up 2.79% at HK$3.32, with a turnover of HK$47.8737 million.
China Power (02380) rose by more than 3% in the morning session. As of the time of writing, it increased by 2.79% to HK$3.32, with a turnover of HK$47.8737 million.
On the news front, China Power announced on March 23, 2025, that its performance for the year 2025 achieved revenue of approximately HK$49.029 billion, annual profit of approximately HK$5.918 billion, earnings per share of HK$0.24, and a final dividend of HK$0.168 per share (an increase of 3.7% compared to the previous year), with a dividend payout ratio increased to 70%. Operating cash flow reached HK$18.518 billion, a significant year-on-year increase of 74.35%. Coupled with prudent optimization of capital expenditure, free cash flow showed a strong rebound. As of December 31, 2025, the company had approximately HK$6.378 billion in cash and cash equivalents.
In terms of revenue structure, the proportion of revenue from clean energy increased from 59.48% in the previous year to 64.51%. This includes wind power revenue of HK$12.651 billion (25.80%), solar power revenue of HK$9.8 billion (19.99%), and hydroelectric power revenue of HK$4.775 billion (9.74%). Thermal power revenue was HK$17.401 billion (35.49%), and benefited from a decline in coal prices and efficient procurement, with a profit increase of 45.76% year-on-year, providing important support for the company's cash flow. In addition, State Power Investment Corporation has designated China Power as a "comprehensive clean energy flagship listed company" and a "comprehensive clean energy industry platform", with strong support from the group. The company is accelerating the development of an integrated energy platform for water, fire, wind, and solar power.
Related Articles

BIOSTAR PHARM-B(02563): Expected audit reservation opinion

MNSO (09896) spent $228,500 on March 24 to buy back 55,600 shares.

UNITED LAB(03933): Phase II clinical study of class 1 innovative drug UBT251 injection has been completed in Chinese type 2 diabetes patients.
BIOSTAR PHARM-B(02563): Expected audit reservation opinion

MNSO (09896) spent $228,500 on March 24 to buy back 55,600 shares.

UNITED LAB(03933): Phase II clinical study of class 1 innovative drug UBT251 injection has been completed in Chinese type 2 diabetes patients.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


